KTC1101

SKU: orb2813881

Description

KTC1101 is an orally bioavailable pan-phosphoinositide 3-kinase (PI3K) inhibitor that suppresses tumor cell proliferation and modulates the tumor microenvironment. It demonstrates anti-tumor activity in preclinical models by inhibiting downstream AKT and mTOR phosphorylation, making it a useful tool for oncology research in both in vitro and in vivo settings.

Research Area

Signal Transduction

Key Properties

• CAS Number: 2764833-47-6
• MW: 476.48
• Purity: 98.75%
• Formula: C₂₁H₂₆F₂N₈O₃
• SMILES: FC(F)C1=NC=2C(OC)=CC(N)=CC2N1C=3N=C(N=C(N3)N4CCOCCC4)N5CCOCC5
• Target: mTOR,Akt,PI3K
• Solubility: DMSO:20 mg/mL (41.97 mM)

Bioactivity

• Target IC50:
  PI3Kγ:17.09 nM|PI3Kβ:36.29 nM|PI3Kα:3.72 nM|PI3Kδ:1.22 nM
• In Vivo:
  In mice, KTC1101 (100 mg/kg) has good oral effect, Tmax is 0.67 h, Cmax is 1.66 μg/mL, AUC0-t is 9.33 μg/mL*h. KTC1101 (100 mg/kg) showed favorable tumor inhibition in mice in four tumor models tested (PC3, CAL33, and HSC2).
• In Vitro:
  The IC50 values of KTC1101 for PI3Kα, PI3Kβ, PI3Kδ and PI3Kγ were 3.72 nM, 36.29 nM, 1.22 nM and 17.09 nM, respectively. KTC1101 effectively inhibited the PI3K signaling pathway, and the phosphorylation of PI3K downstream effector AKT and mTOR was decreased.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

KTC 1101, KTC1101

Compound Identifiers

PubChem CID

171364488